| Literature DB >> 17726916 |
Abstract
In 1936, two clinical reviews, one by de Morsier, the other by L'Hermitte and de Ajuriaguerra, formulated an approach to visual hallucinations that continues to this day. Breaking with previous traditions, the papers championed visual hallucinations as worthy of study in their own right, de-emphasizing the clinical significance of their visual contents and distancing them from visual illusions. De Morsier described a set of visual hallucinatory syndromes based on the wider neurological and psychiatric context, many of which remain relevant today; however, one-the Charles Bonnet Syndrome-sparked 70 years of controversy over the role of the eye. Here, the history of visual hallucinatory syndromes and the eye dispute is reviewed, together with advances in perceptual neuroscience that question core assumptions of our current approach. From a neurobiological perspective, three syndromes emerge that relate to specific dysfunctions of afferent, cholinergic and serotonergic visual circuitry and promise future therapeutic advances.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17726916 PMCID: PMC3181850
Source DB: PubMed Journal: Dialogues Clin Neurosci ISSN: 1294-8322 Impact factor: 5.986
de Morsier's classification of visual hallucinatory syndromes.
| Charles Bonnet syndrome | Visual hallucinations in old age without dementia | Selective degeneration of pulvino-cortical pathways |
| Neurodegenerative | Dementia and visual hallucinations | Visual system involvement in Alzheimer's or Pick's disease |
| zingerle syndrome | Forced movements, vestibular symptoms, and hemianopic visual hallucinations | Parietal lesion involving vestibular, motor, and pulvino-cortical pathways |
| L'Hermitte syndrome (diencephalic/peduncular lesions) | Lateralized pain, paresthesiae, sensory loss and visual hallucinations/oculomotor nerve palsies and visual hallucinations | Pulvinar lesion |
| de Clérambault syndrome (mental automatisms) | Auditory and visual hallucinations in chronic psychosis | Combined temporal parietal and occipital dysfunction |
| Vascular lesions of the occipital lobe | Visual hallucinations in association with a visual field defect | Infarct of visual cortex/pathways |
| Cerebral tumors/ intracranial hypertension | Visual hallucinations and localizing signs of space-occupying lesion | Visual system involvement in occipital temporal or parietal lobe lesions/3rd, 4th ventricle tumours |
| Inflammation | Visual hallucinations in context of delirium | Excitation of extended visual system by encephalitis/ fever |
| Intoxication | Visual hallucinations in context of delirium | Excitation of extended visual system by atropine, digitalis, barbiturates, insulin, mescaline, hashish |
| Epilepsy | Visual hallucinations in context of epilepsy | Seizure involving extended visual system |
| Cerebral trauma | Acute and chronic visual hallucinations following traumatic injury | Involvement of extended visual system |
| Monocular hallucinations | Central field scotoma with hallucinations | Combined retrobulbar and cerebral factors, eg, delirium tremens |
Visual hallucinatory syndromes not included by de Morsier. LSD, lysergic acid diethylamide; MDMA, 3,4-methylenedioxymethamphetamine; PTSD, post-traumatic stress disorder
| Eye disease (specifically excluded) |
| Parkinson's disease |
| Lewy body dementia |
| Narcolepsy |
| Migraine |
| LSD/MDMA (ecstasy) |
| PTSD |
| Sensory deprivation |
| Stroboscopic stimulation |
Treatment approaches. 5-HT, serotonin; CNS, central nervous system
| Reassurance | Mainstay of treatment for patients with self-limiting visual hallucinations related to eye disease. |
| Ophthalmic intervention | Hallucinations may resolve after treatment of ophthalmic condition eg, cataract extraction or correction of refractive error. |
| Antiepileptics | Carbamazepine, sodium valproate, phenytoin, and gabapentin may be helpful in visual hallucinations related to visual pathway infarcts or eye disease. |
| Antipsychotic | A range of typical and atypical neuroleptics have been used to treat visual hallucinations associated with eye disease, with mixed success. |
| Cholinesterase inhibitors | Donepezil may improve visual hallucinations, particularly in patients with cognitive impairment. |
| 5-HT | Cisapride and Ondansetron have been used to treat visual hallucinations in both Parkinson's disease and eye disease. |
| Cerebral blood flow | Acetazolamide has been used to treat the visual hallucinations of migraine aura status. |
| CNS stimulants | Methylphenidate hydrochloride (Ritalin) reduces visual hallucinations in patients with dementia. |